AlphaFold predicted structure
CALM2 · P0DP24

Mean pLDDT
85.8/ 100
Confident
149 residues
Confidence breakdown
- Very high(≥ 90)46%
- Confident(70–90)45%
- Low(50–70)7%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
calmodulin 2
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Catecholaminergic polymorphic VT
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedLong QT syndrome
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedShort QT syndrome
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedlong QT syndrome 15
Romano-Ward syndrome
familial long QT syndrome
long QT syndrome 1
Prolonged QT interval
bacterial infectious disease
Abnormality of the cardiovascular system
sudden infant death syndrome
alcohol drinking
catecholaminergic polymorphic ventricular tachycardia
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Calmodulin-2
Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:26969752, PubMed:27165696). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:26969752, PubMed:27165696, PubMed:35568036). Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent protein kinase type II (CaMK2), and phosphatases (PubMed:16760425, PubMed:26969752, PubMed:27165696, PubMed:35568036). Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis (PubMed:16760425). Mediates calcium-dependent inactivation of CACNA1C (PubMed:26969752). Positively regulates calcium-activated potassium channel activity of KCNN2 (PubMed:27165696)
CALM2 · P0DP24

Mean pLDDT
85.8/ 100
Confident
149 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0